Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (291-300 of 430) with videos related to

Pageof 43
Sort By:
JNCI Cancer Spectrum|November 22, 2023
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancerSenna W M Lammers, Sandra M E Geurts, Irene E G van Hellemond, et al.
Breast Cancer Research and Treatment|September 27, 2008
Validation of 70-gene prognosis signature in node-negative breast cancerJ M Bueno-de-Mesquita, S C Linn, R Keijzer, et al.
BMC Cancer|September 4, 2015
The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07)L M van Roozendaal, J H W de Wilt, T van Dalen, et al.
ESMO Open|February 8, 2025
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trialS W M Lammers, S M E Geurts, K E P E Hermans, et al.
Breast Cancer Research and Treatment|March 4, 2020
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trialIrene E G van Hellemond, Carolien H Smorenburg, Petronella G M Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB TrialSonja B Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, et al.
The Lancet. Oncology|October 17, 2017
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trialVivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
BMC Cancer|July 3, 2017
Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)L M van Roozendaal, M L G Vane, T van Dalen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01)Anne F de Groot, Danielle Cohen, Joan B Heijns, et al.
Pageof 43

Showing results (291-300 of 430) with videos related to

Sort By:
Pageof 43
JNCI Cancer Spectrum|November 22, 2023
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancerSenna W M Lammers, Sandra M E Geurts, Irene E G van Hellemond, et al.
Breast Cancer Research and Treatment|September 27, 2008
Validation of 70-gene prognosis signature in node-negative breast cancerJ M Bueno-de-Mesquita, S C Linn, R Keijzer, et al.
BMC Cancer|September 4, 2015
The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07)L M van Roozendaal, J H W de Wilt, T van Dalen, et al.
ESMO Open|February 8, 2025
The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trialS W M Lammers, S M E Geurts, K E P E Hermans, et al.
Breast Cancer Research and Treatment|March 4, 2020
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trialIrene E G van Hellemond, Carolien H Smorenburg, Petronella G M Peer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB TrialSonja B Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, et al.
The Lancet. Oncology|October 17, 2017
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trialVivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
BMC Cancer|July 3, 2017
Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)L M van Roozendaal, M L G Vane, T van Dalen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2025
Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01)Anne F de Groot, Danielle Cohen, Joan B Heijns, et al.
Pageof 43